Skip to main content
ORIC
NASDAQ Life Sciences

ORIC's Rinzimetostat Shows 'Best-in-Disease' Potential, Advances to Phase 3 Trial

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$9.53
Mkt Cap
$966.45M
52W Low
$4.52
52W High
$14.93
52W Position info
111% above low
Off High info
36% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ORIC has more than doubled off its 52-week low of $4.52.

Summary

ORIC Pharmaceuticals reported Q1 2026 financial results and significant operational updates, primarily highlighting the advancement of its lead oncology candidate, rinzimetostat. The company selected the Recommended Phase 3 Dose (RP3D) for rinzimetostat in combination with darolutamide for the Himalayas-1 global Phase 3 trial in post-abiraterone mCRPC, expected to initiate in 1H 2026. Dose optimization data for rinzimetostat demonstrated a highly differentiated safety profile and landmark rPFS rates (93%, 84%, 84% at 3, 4, and 5 months) consistent with a competitor and superior to standard of care therapies. This strong clinical data supports a potential "best-in-disease" profile, significantly de-risking the program. Furthermore, ORIC reported a robust cash position of approximately $420 million, extending its runway into 2H 2028, well beyond the anticipated primary endpoint readout of the first Phase 3 trial. Investors will now watch for the initiation of the Himalayas-1 trial and further clinical updates for both rinzimetostat and enozertinib in the second half of 2026.

At the time of this announcement, ORIC was trading at $9.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $966.4M. The 52-week trading range was $4.52 to $14.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ORIC - Latest Insights

ORIC
Nov 16, 2026, 4:20 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $7.70 info
Change: +$0.180 (+2%) info
Market Cap: $800.273M info
ORIC
Nov 16, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $7.70 info
Change: +$0.180 (+2%) info
Market Cap: $800.273M info
ORIC
Nov 16, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $7.70 info
Change: +$0.180 (+2%) info
Market Cap: $800.273M info
ORIC
Oct 23, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.32
Real-time Price: $7.70 info
Change: -$5.62 (-42%) info
Market Cap: $800.273M info
ORIC
Oct 23, 2026, 3:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $13.85
Real-time Price: $7.70 info
Change: -$6.15 (-44%) info
Market Cap: $800.273M info